ID

17214

Descripción

ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity; ODM derived from: https://clinicaltrials.gov/show/NCT00263965

Link

https://clinicaltrials.gov/show/NCT00263965

Palabras clave

Versiones (1)
  1. 1/9/16 1/9/16 -
Subido en

1 de septiembre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes NCT00263965

Inglés

Eligibility Type 2 Diabetes NCT00263965

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
provision of a written informed consent
Descripción

Informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
men or women who are 30-70 years of age
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
female patients: postmenopausal, hysterectomized
Descripción

female patients: postmenopausal, hysterectomized

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0020699
diagnosed with type 2 diabetes
Descripción

type 2 diabetes

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
Descripción

Treatment with diet alone or with a single oral antidiabetic agent or two oral antidiabetic agents

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011878
UMLS CUI [2]
C0359086
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
type 1 diabetes
Descripción

type 1 diabetes

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011854
new york heart association heart failure class iii or iv
Descripción

NYHA

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1275491
treatment with chronic insulin
Descripción

Insulin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021641
history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)
Descripción

hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist, fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1257987
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0033228
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0025598
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0360714
history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
Descripción

drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0410220
UMLS CUI [2,1]
C0151576
UMLS CUI [2,2]
C0458082
UMLS CUI [3]
C0428321
UMLS CUI [4]
C0027947
creatinine levels above twice the normal range
Descripción

creatinine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201975
creatine kinase above 3 times the upper limit of normal
Descripción

creatine kinase

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201973
received any investigational product in other clinical studies within 12 weeks
Descripción

investigational drug

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Descripción

Comorbidity compromising patient safety or successful participation in clinical study

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
Volver a la parte superior de la página

Similar models

Eligibility Type 2 Diabetes NCT00263965

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed consent
Item
provision of a written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
men or women who are 30-70 years of age
boolean
C0001779 (UMLS CUI [1])
female patients: postmenopausal, hysterectomized
Item
female patients: postmenopausal, hysterectomized
boolean
C0232970 (UMLS CUI [1])
C0020699 (UMLS CUI [2])
type 2 diabetes
Item
diagnosed with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Treatment with diet alone or with a single oral antidiabetic agent or two oral antidiabetic agents
Item
treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
boolean
C0011878 (UMLS CUI [1])
C0359086 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
type 1 diabetes
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
NYHA
Item
new york heart association heart failure class iii or iv
boolean
C1275491 (UMLS CUI [1])
Insulin
Item
treatment with chronic insulin
boolean
C0021641 (UMLS CUI [1])
hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist, fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor
Item
history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)
boolean
C0020517 (UMLS CUI [1,1])
C1257987 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0033228 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0360714 (UMLS CUI [4,2])
drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia
Item
history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
boolean
C0410220 (UMLS CUI [1])
C0151576 (UMLS CUI [2,1])
C0458082 (UMLS CUI [2,2])
C0428321 (UMLS CUI [3])
C0027947 (UMLS CUI [4])
creatinine
Item
creatinine levels above twice the normal range
boolean
C0201975 (UMLS CUI [1])
creatine kinase
Item
creatine kinase above 3 times the upper limit of normal
boolean
C0201973 (UMLS CUI [1])
investigational drug
Item
received any investigational product in other clinical studies within 12 weeks
boolean
C0013230 (UMLS CUI [1])
Comorbidity compromising patient safety or successful participation in clinical study
Item
any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial